Table 3.

Impact of possible prognostic factors on recurrence‐free survival and progression‐free survival in 106 patients.

	Recurrence				Progression
	Univariable	P	Multivariable	P	Univariable	P	Multivariable	P
	HR (95% CI)		HR (95% CI)		HR (95% CI)		HR (95% CI)
Sex (male vs female)	1.04 (0.50–2.16)	0.92			0.49 (0.17–1.48)	0.21
Positive cytology	1.24 (0.57–2.67)	0.59			0.46 (0.10–2.08)	0.31
Multiple tumours	1.01 (0.53–1.95)	0.97			1.38 (0.45–4.25)	0.57
Tumour diameter >30 mm	0.85 (0.37–1.96)	0.71			1.56 (0.42–5.83)	0.51
Non‐papillary tumour	0.68 (0.24–1.93)	0.47			1.90 (0.52–6.92)	0.33
Sessile tumour	0.96 (0.48–1.89)	0.9			1.27 (0.43–3.81)	0.67
Recurrent tumour	2.34 (1.06–5.18)	0.035	1.60 (0.59–4.37)	0.36	2.02 (0.55–7.38)	0.29
Concomitant CIS	1.06 (0.57–1.96)	0.86	0.97 (0.46–2.08)	0.94	0.78 (0.26–2.35)	0.65
History of UTUC	2.74 (1.25–6.02)	0.01	2.47 (0.97–6.30)	0.06	1.81 (0.50–6.61)	0.37
Maintenance therapy	0.52 (0.27–1.01)	0.052	0.51 (0.24–1.06)	0.07	0.36 (0.12–1.11)	0.08	0.45 (0.14–1.43)	0.18
pT1a/b	0.88 (0.42–1.82)	0.73			4.93 (1.60–15.2)	0.006	3.18 (0.93–10.9)	0.07
Positive horizontal margin	1.74 (0.86–3.5)	0.12	2.17 (0.94–5.03)	0.07	‐	‐	‐	‐
Positive vertical margin	1.55 (0.54–4.39)	0.41			9.78 (2.82–33.9)	<0.001	6.93 (1.84–26.1)	0.004
ReTUR	1.29 (0.63–2.35)	0.55			1.10 (0.35–3.42)	0.87

UTUC, upper urinary tract urothelial carcinoma.